InflaRx N.V.
General information
InflaRx N.V.
Winzerlaer Str. 2
07745 Jena, Thuringia
Germany
Contact person: Niels C. Riedemann, Chief Executive Officer, Board Executive Director
Company main phone: +49 (3641) 508180
Company main fax: +49 (3641) 508181
Website: https://www.inflarx.de
Winzerlaer Str. 2
07745 Jena, Thuringia
Germany
Contact person: Niels C. Riedemann, Chief Executive Officer, Board Executive Director
Company main phone: +49 (3641) 508180
Company main fax: +49 (3641) 508181
Website: https://www.inflarx.de
| Year founded: | 2007 |
| Source of foundation: | Independent foundation |
| No. of employees: |
Worldwide: 62 |
Corporate description / mission:
InflaRx is a clinical-stage biopharmaceutical company focused on applying the proprietary anti-C5a technology to discover and develop potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.
InflaRx is a clinical-stage biopharmaceutical company focused on applying the proprietary anti-C5a technology to discover and develop potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2017
Headquarters: HQ: Yes
IPO (year): 2017
Remarks on ownership / listings
InflaRx has offices in Jena and Munich, Germany and a research facility in Ann Arbor, Michigan.
InflaRx has offices in Jena and Munich, Germany and a research facility in Ann Arbor, Michigan.
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
| Distribution: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 1 | |
| Phase I: | 4 | |
| Phase II: | 2 | |
| Phase III: | 4 | |
| On the market: | 2 |
Description of products:
Vilobelimab (IFX-1)
IFX-2
INF904
Vilobelimab (IFX-1)
IFX-2
INF904
Technology used:
Anti C5a Technology
Anti C5a Technology
Financing details
| Market cap. / valuation: | USD 141.91M |
© 2025 Biotechgate by Venture Valuation